JP2023541170A5 - - Google Patents
Info
- Publication number
- JP2023541170A5 JP2023541170A5 JP2023516545A JP2023516545A JP2023541170A5 JP 2023541170 A5 JP2023541170 A5 JP 2023541170A5 JP 2023516545 A JP2023516545 A JP 2023516545A JP 2023516545 A JP2023516545 A JP 2023516545A JP 2023541170 A5 JP2023541170 A5 JP 2023541170A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- approximately
- dose
- aat
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063078658P | 2020-09-15 | 2020-09-15 | |
| US63/078,658 | 2020-09-15 | ||
| US202163180487P | 2021-04-27 | 2021-04-27 | |
| US63/180,487 | 2021-04-27 | ||
| PCT/US2021/050247 WO2022060721A2 (en) | 2020-09-15 | 2021-09-14 | Methods for the reduction of z-aat protein levels |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023541170A JP2023541170A (ja) | 2023-09-28 |
| JP2023541170A5 true JP2023541170A5 (https=) | 2024-09-24 |
| JP7846095B2 JP7846095B2 (ja) | 2026-04-14 |
Family
ID=78080560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023516545A Active JP7846095B2 (ja) | 2020-09-15 | 2021-09-14 | Ｚ－ａａｔタンパク質のレベルを低下させる方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230348905A1 (https=) |
| EP (1) | EP4214316A2 (https=) |
| JP (1) | JP7846095B2 (https=) |
| KR (1) | KR20230067648A (https=) |
| AU (1) | AU2021345026A1 (https=) |
| BR (1) | BR112023004756A2 (https=) |
| CA (1) | CA3192372A1 (https=) |
| CO (1) | CO2023003958A2 (https=) |
| MX (1) | MX2023003066A (https=) |
| TW (1) | TW202220675A (https=) |
| WO (1) | WO2022060721A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201620526A (zh) | 2014-06-17 | 2016-06-16 | 愛羅海德研究公司 | 用於抑制α－１抗胰蛋白酶基因表現之組合物及方法 |
| MX2021015003A (es) | 2019-06-06 | 2022-01-24 | Arrowhead Pharmaceuticals Inc | Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd). |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL9201440A (nl) | 1992-08-11 | 1994-03-01 | Univ Leiden | Triantennaire clusterglycosiden, hun bereiding en toepassing. |
| WO2008016391A2 (en) | 2006-01-31 | 2008-02-07 | The Board Of Trustees Of The Leland Stanford Junior University | Self-complementary parvoviral vectors, and methods for making and using the same |
| WO2012178033A2 (en) * | 2011-06-23 | 2012-12-27 | Alnylam Pharmaceuticals, Inc. | Serpina1 sirnas: compositions of matter and methods of treatment |
| US9458457B2 (en) | 2013-07-03 | 2016-10-04 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of alpha-1 antitrypsin by double-stranded RNA |
| CA3011946A1 (en) | 2016-03-07 | 2017-09-14 | Arrowhead Pharmaceuticals, Inc. | Targeting ligands for therapeutic compounds |
| SG11201901841TA (en) | 2016-09-02 | 2019-03-28 | Arrowhead Pharmaceuticals Inc | Targeting ligands |
| CN110268060B (zh) | 2017-01-10 | 2024-07-26 | 箭头药业股份有限公司 | α-1抗胰蛋白酶(AAT)RNAi物质、包含AAT RNAi物质的组合物和使用方法 |
| MX2021015003A (es) | 2019-06-06 | 2022-01-24 | Arrowhead Pharmaceuticals Inc | Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd). |
-
2021
- 2021-09-14 JP JP2023516545A patent/JP7846095B2/ja active Active
- 2021-09-14 US US18/026,340 patent/US20230348905A1/en active Pending
- 2021-09-14 BR BR112023004756A patent/BR112023004756A2/pt unknown
- 2021-09-14 EP EP21787228.2A patent/EP4214316A2/en active Pending
- 2021-09-14 KR KR1020237012414A patent/KR20230067648A/ko active Pending
- 2021-09-14 MX MX2023003066A patent/MX2023003066A/es unknown
- 2021-09-14 WO PCT/US2021/050247 patent/WO2022060721A2/en not_active Ceased
- 2021-09-14 CA CA3192372A patent/CA3192372A1/en active Pending
- 2021-09-14 AU AU2021345026A patent/AU2021345026A1/en active Pending
- 2021-09-15 TW TW110134359A patent/TW202220675A/zh unknown
-
2023
- 2023-03-28 CO CONC2023/0003958A patent/CO2023003958A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5869469B2 (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| JP2022535127A5 (https=) | ||
| JP2025096283A5 (https=) | ||
| US20240100125A1 (en) | Synergistic effect of a fxr agonist and ifn for the treatment of hbv infection | |
| JP2023541170A5 (https=) | ||
| RU2371195C2 (ru) | Способ лечения вирусных инфекций | |
| JP3838034B2 (ja) | Ｃ型肝炎治療効果の改善剤及びその応用 | |
| EP3999069B1 (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection | |
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| HK40066536A (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection | |
| HK40066536B (en) | Synergistic effect of eyp001 and pegylated ifn-alpha for the treatment of hbv infection | |
| JP2006515011A (ja) | Ｈｃｖ併用療法 | |
| CN111084808A (zh) | 咳特灵制剂在治疗乙型肝炎中的应用 | |
| RU2021139235A (ru) | Способы лечения дефицита альфа-1-антитрипсина (aatd) | |
| US20230346888A1 (en) | Method and composition of treatment or prevention of coronavirus infection | |
| JP5500751B2 (ja) | 肝移植後の再感染防御剤 | |
| EA046230B1 (ru) | Синергическое действие eyp001 и ifn при лечении инфекции hbv | |
| CN1297272C (zh) | 马来酸氯苯那敏的新用途 | |
| JP2023543131A5 (https=) | ||
| CN101180053A (zh) | 铁在发病机制中发挥作用的肝病的治疗 | |
| WO2021098771A1 (en) | Treatment method with iap inhibitor | |
| JP2025508660A5 (https=) | ||
| CN103127511A (zh) | 治疗丙型肝炎的新型药物组合物 | |
| CN102470162A (zh) | 用于治疗难治性c型慢性肝炎的药剂以及方法 | |
| MXPA06001695A (en) | Method of treating viral infections |